Cardiovascular Systems’ (CSII) Market Perform Rating Reiterated at William Blair

William Blair reissued their market perform rating on shares of Cardiovascular Systems (NASDAQ:CSII) in a research report report published on Thursday morning.

Several other research analysts have also commented on CSII. Needham & Company LLC lowered shares of Cardiovascular Systems from a buy rating to a hold rating and lowered their price objective for the company from $33.11 to $23.00 in a research note on Friday, December 15th. Raymond James Financial reiterated a hold rating on shares of Cardiovascular Systems in a research note on Monday, December 4th. Zacks Investment Research raised shares of Cardiovascular Systems from a sell rating to a hold rating in a report on Monday, November 13th. Finally, Citigroup began coverage on shares of Cardiovascular Systems in a report on Thursday, September 21st. They set a market perform rating on the stock. Two analysts have rated the stock with a sell rating, five have given a hold rating and one has assigned a buy rating to the company’s stock. The stock currently has a consensus rating of Hold and an average price target of $31.50.

Shares of Cardiovascular Systems (NASDAQ:CSII) opened at $23.37 on Thursday. Cardiovascular Systems has a 12-month low of $23.00 and a 12-month high of $33.11. The company has a market cap of $766.32, a PE ratio of -389.50 and a beta of 2.52. The company has a debt-to-equity ratio of 0.18, a current ratio of 4.30 and a quick ratio of 3.83.

Cardiovascular Systems (NASDAQ:CSII) last released its quarterly earnings data on Wednesday, October 25th. The medical device company reported ($0.06) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.08) by $0.02. Cardiovascular Systems had a negative net margin of 0.93% and a positive return on equity of 0.74%. The firm had revenue of $49.70 million during the quarter, compared to analysts’ expectations of $51.00 million. During the same period last year, the business earned ($0.06) earnings per share. Cardiovascular Systems’s revenue was down .2% compared to the same quarter last year. sell-side analysts anticipate that Cardiovascular Systems will post -0.05 EPS for the current fiscal year.

Several institutional investors have recently made changes to their positions in the company. Jennison Associates LLC boosted its position in shares of Cardiovascular Systems by 22.7% in the 2nd quarter. Jennison Associates LLC now owns 12,567 shares of the medical device company’s stock worth $405,000 after buying an additional 2,323 shares in the last quarter. Vanguard Group Inc. raised its stake in shares of Cardiovascular Systems by 12.6% during the 2nd quarter. Vanguard Group Inc. now owns 1,864,604 shares of the medical device company’s stock worth $60,096,000 after purchasing an additional 208,248 shares in the last quarter. State Street Corp raised its stake in shares of Cardiovascular Systems by 0.9% during the 2nd quarter. State Street Corp now owns 677,462 shares of the medical device company’s stock worth $21,828,000 after purchasing an additional 6,074 shares in the last quarter. Timpani Capital Management LLC raised its stake in shares of Cardiovascular Systems by 24.2% during the 2nd quarter. Timpani Capital Management LLC now owns 116,397 shares of the medical device company’s stock worth $3,751,000 after purchasing an additional 22,649 shares in the last quarter. Finally, Parametric Portfolio Associates LLC raised its stake in shares of Cardiovascular Systems by 77.8% during the 2nd quarter. Parametric Portfolio Associates LLC now owns 59,884 shares of the medical device company’s stock worth $1,930,000 after purchasing an additional 26,212 shares in the last quarter. 74.86% of the stock is currently owned by institutional investors and hedge funds.

WARNING: “Cardiovascular Systems’ (CSII) Market Perform Rating Reiterated at William Blair” was originally posted by Community Financial News and is the sole property of of Community Financial News. If you are viewing this news story on another site, it was illegally copied and republished in violation of U.S. and international copyright & trademark legislation. The original version of this news story can be accessed at https://www.com-unik.info/2017/12/25/cardiovascular-systems-csii-market-perform-rating-reiterated-at-william-blair.html.

About Cardiovascular Systems

Cardiovascular Systems, Inc is a medical technology company. The Company is engaged in treating patients suffering from peripheral and coronary artery diseases, including those with arterial calcium. The Company develops an orbital atherectomy technology for both peripheral and coronary commercial applications.

Analyst Recommendations for Cardiovascular Systems (NASDAQ:CSII)

What are top analysts saying about Cardiovascular Systems? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Cardiovascular Systems and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit